1. 1266. Characterization of Shifts in Minimum Inhibitory Concentrations During Treatment with Cefiderocol or Comparators in the Phase 3 CREDIBLE-CR and APEKS-NP Studies. (31st December 2020) Authors: Takemura, Miki; Yamano, Yoshinori; Matsunaga, Yuko; Ariyasu, Mari; Echols, Roger; Den Nagata, Tsutae Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S649 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1271. Efficacy and Safety of Cefiderocol and Best Available Therapy in Patients with Serious Infections Caused by Carbapenem-Resistant Gram-Negative Infections: Results of the Pathogen-Focused Phase 3 CREDIBLE-CR Study. (31st December 2020) Authors: Bassetti, Matteo; Echols, Roger; Matsunaga, Yuko; Portsmouth, Simon; Ariyasu, Mari; Toyoizumi, Kiichiro; Doi, Yohei; Doi, Yohei; Den Nagata, Tsutae Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S652 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1285. Outcomes in Patients with Gram-Negative Bacteremia from Phase 2 and Phase 3 Clinical Trials of Cefiderocol, a Novel Siderophore Cephalosporin. (31st December 2020) Authors: Kinoshita, David PatersonDavid PatersonMasahiro; Toyoizumi, Kiichiro; Matsunaga, Yuko; Echols, Roger Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S658 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 1292. Safety Profile of the Novel Siderophore Cephalosporin Cefiderocol in Randomized Phase 2 and Phase 3 Clinical Studies of Serious Gram-Negative Infections. (31st December 2020) Authors: Matsunaga, Yuko; Sonoyama, Takuhiro; Casanova, Luis; Nagata, Tsutae Den; Echols, Roger; De Gregorio, Fabio; Ogura, Eriko; Portsmouth, Simon Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S661 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 1316. Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol in Critically Ill Patients. (31st December 2020) Authors: Katsube, Takayuki; Kawaguchi, Nao; Matsunaga, Yuko; Ariyasu, Mari; Den Nagata, Tsutae; Portsmouth, Simon; Paterson, David; Paterson, David; Satlin, Michael J; Zeitlinger, Markus; Echols, Roger; Wajima, Toshihiro Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S669 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 165. Cefiderocol Treatment for Serious Infections Caused by Carbapenem-resistant Bacteria: Post-hoc Analysis of Outcomes by Pathogen in the CREDIBLE-CR Study. (31st December 2020) Authors: Matsunaga, Yuko; Ariyasu, Mari; Takemura, Miki; Yamano, Yoshinori; Toyoizumi, Kiichiro; Kinoshita, Masahiro; Echols, Roger; Den Nagata, Tsutae Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S212 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Issue 2 (February 2021) Authors: Wunderink, Richard G; Matsunaga, Yuko; Ariyasu, Mari; Clevenbergh, Philippe; Echols, Roger; Kaye, Keith S; Kollef, Marin; Menon, Anju; Pogue, Jason M; Shorr, Andrew F; Timsit, Jean-Francois; Zeitlinger, Markus; Nagata, Tsutae D Journal: Lancet infectious diseases Issue: Volume 21:Issue 2(2021) Page Start: 213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Issue 2 (February 2021) Authors: Bassetti, Matteo; Echols, Roger; Matsunaga, Yuko; Ariyasu, Mari; Doi, Yohei; Ferrer, Ricard; Lodise, Thomas P; Naas, Thierry; Niki, Yoshihito; Paterson, David L; Portsmouth, Simon; Torre-Cisneros, Julian; Toyoizumi, Kiichiro; Wunderink, Richard G; Nagata, Tsutae D Journal: Lancet infectious diseases Issue: Volume 21:Issue 2(2021) Page Start: 226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Erratum to: Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. (17th September 2021) Authors: Katsube, Takayuki; Nicolau, David P; Rodvold, Keith A; Wunderink, Richard G; Echols, Roger; Matsunaga, Yuko; Menon, Anju; Portsmouth, Simon; Wajima, Toshihiro Journal: Journal of antimicrobial chemotherapy Issue: Volume 76:Number 11(2021) Page Start: 3069 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. (12th August 2021) Authors: Katsube, Takayuki; Nicolau, David P; Rodvold, Keith A; Wunderink, Richard G; Echols, Roger; Matsunaga, Yuko; Menon, Anju; Portsmouth, Simon; Wajima, Toshihiro Journal: Journal of antimicrobial chemotherapy Issue: Volume 76:Number 11(2021) Page Start: 2902 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗